A review of the clinical utility of duloxetine in the treatment of diabetic peripheral neuropathic pain

References

• Centers for Disease Control and Prevention [webpage on the Internet]National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States AGAUS Department of Health and Human Services2014 Available from: http://www.cdc.gov/diabetes/data/statistics/2014statisticsreport.htmlAccessed April 2, 2015
   Google Scholar
• BarrettAMLuceroMALeTRobinsonRLDworkinRHChappellASEpidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a reviewPain Med20078Suppl 2S50S6217714116
   PubMed Web of Science ®Google Scholar
• DaviesMBrophySWilliamsRTaylorAThe prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetesDiabetes Care20062971518152216801572
   PubMed Web of Science ®Google Scholar
• National Institute of Diabetes and Digestive and Kidney Diseases [webpage on the Internet]Diabetic Neuropathies: The Nerve Damage of Diabetes2013 Available from: http://diabetes.niddk.nih.gov/dm/pubs/neuropathies/Accessed April 2, 2015
   Google Scholar
• BoultonAJVinikAIArezzoJCDiabetic neuropathies: a statement by the American Diabetes AssociationDiabetes Care200528495696215793206
   PubMed Web of Science ®Google Scholar
• GalerBSGianasAJensenMPPainful diabetic polyneuropathy: epidemiology, pain description, and quality of lifeDiabetes Res Clin Pract200047212312810670912
   PubMed Web of Science ®Google Scholar
• No authors listedStandards of medical care in diabetes – 2015: summary of revisionsDiabetes Care201538SupplS425537706
   PubMedGoogle Scholar
• CallaghanBCLittleAAFeldmanELHughesRAEnhanced glucose control for preventing and treating diabetic neuropathyCochrane Database Syst Rev20126CD00754322696371
   PubMed Web of Science ®Google Scholar
• ZieglerDFonsecaVFrom guideline to patient: a review of recent recommendations for pharmacotherapy of painful diabetic neuropathyJ Diabetes Complications201529114615625239450
   PubMed Web of Science ®Google Scholar
• American Diabetes Association(9) Microvascular complications and foot careDiabetes Care201538SupplS58S6625537710
   PubMedGoogle Scholar
• BrilVEnglandJFranklinGMEvidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and RehabilitationNeurology201176201758176521482920
   PubMed Web of Science ®Google Scholar
• HandelsmanYMechanickJIBlondeLAmerican Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care planEndocr Pract201117Suppl 215321474420
   PubMed Web of Science ®Google Scholar
• LeskoLJZinehIHuangSMWhat is clinical utility and why should we care?Clin Pharmacol Ther201088672973321081937
   PubMed Web of Science ®Google Scholar
• GaoYNingGJiaWPDuloxetine versus placebo in the treatment of patients with diabetic neuropathic pain in ChinaChin Med J (Engl)2010123223184319221163113
   PubMed Web of Science ®Google Scholar
• GoldsteinDJLuYDetkeMJLeeTCIyengarSDuloxetine vs placebo in patients with painful diabetic neuropathyPain20051161–210911815927394
   PubMed Web of Science ®Google Scholar
• RaskinJPritchettYLWangFA double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic painPain Med20056534635616266355
   PubMed Web of Science ®Google Scholar
• RaskinJSmithTRWongKDuloxetine versus routine care in the long-term management of diabetic peripheral neuropathic painJ Palliat Med200691294016430342
   PubMed Web of Science ®Google Scholar
• RaskinJWangFPritchettYLGoldsteinDJDuloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety studyPain Med20067537338517014595
   PubMed Web of Science ®Google Scholar
• RowbothamMCArslanianANothaftWEfficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic painPain2012153486286822386472
   PubMed Web of Science ®Google Scholar
• SkljarevskiVDesaiahDZhangQEvaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic painDiabetes Metab Res Rev200925762363119637208
   PubMed Web of Science ®Google Scholar
• TanenbergRJIrvingGARisserRCDuloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparisonMayo Clin Proc201186761562621719618
   PubMed Web of Science ®Google Scholar
• TesfayeSWilhelmSLledoADuloxetine and pregabalin: high-dose monotherapy or their combination? The “COMBO-DN study” – a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic painPain2013154122616262523732189
   PubMed Web of Science ®Google Scholar
• WernickeJFPritchettYLD’SouzaDNA randomized controlled trial of duloxetine in diabetic peripheral neuropathic painNeurology20066781411142017060567
   PubMed Web of Science ®Google Scholar
• WernickeJFWangFPritchettYLAn open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic painPain Med20078650351317716324
   PubMed Web of Science ®Google Scholar
• BoyleJErikssonMEGribbleLRandomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of lifeDiabetes Care201235122451245822991449
   PubMed Web of Science ®Google Scholar
• KaurHHotaDBhansaliADuttaPBansalDChakrabartiAA comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trialDiabetes Care201134481882221355098
   PubMed Web of Science ®Google Scholar
• AnnemansLAristidesMKubinMReal-Life Data: A Growing NeedISPOR Connections2007135812
   Google Scholar
• ChenSWuNFraserKBoulangerLZhaoYOpioid use and healthcare costs among patients with DPNP initiating duloxetine versus other treatmentsCurr Med Res Opin201026102507251620831456
   PubMed Web of Science ®Google Scholar
• WuNChenSYHallettLAOpioid utilization and health-care costs among patients with diabetic peripheral neuropathic pain treated with duloxetine vs other therapiesPain Pract2011111485620602718
   PubMed Web of Science ®Google Scholar
• ZhaoYWuNChenSBoulangerLPoliceRLFraserKChanges in opioid use and healthcare costs among U.S. patients with diabetic peripheral neuropathic pain treated with duloxetine compared with other therapiesCurr Med Res Opin20102692147215620662557
   PubMed Web of Science ®Google Scholar
• OladapoAOBarnerJCRascatiKLStrasselsSAA retrospective database analysis of neuropathic pain and oral antidiabetic medication use and adherence among Texas adults with type 2 diabetes enrolled in MedicaidClin Ther201234360561322386828
   PubMed Web of Science ®Google Scholar
• ZhaoYSunPWatsonPMedication adherence and healthcare costs among patients with diabetic peripheral neuropathic pain initiating duloxetine versus pregabalinCurr Med Res Opin201127478579221303196
   PubMed Web of Science ®Google Scholar
• BurkeJPSanchezRJJoshiAVCappelleriJCKulakodluMHalpernRHealth care costs in patients with painful diabetic peripheral neuropathy prescribed pregabalin or duloxetinePain Pract201212320921821676163
   PubMed Web of Science ®Google Scholar
• GoreMZlatevaGTaiKSChandranABLeslieDRetrospective evaluation of clinical characteristics, pharmacotherapy and healthcare resource use among patients prescribed pregabalin or duloxetine for diabetic peripheral neuropathy in usual carePain Pract201111216717920723096
   PubMed Web of Science ®Google Scholar
• JohnstonSSUdallMCappelleriJCCost comparison of drug-drug and drug-condition interactions in patients with painful diabetic peripheral neuropathy treated with pregabalin versus duloxetineAm J Health Syst Pharm201370242207221724296843
   PubMed Web of Science ®Google Scholar
• MargolisJCaoZFowlerREvaluation of healthcare resource utilization and costs in employees with pain associated with diabetic peripheral neuropathy treated with pregabalin or duloxetineJ Med Econ201013473874721091395
   PubMedGoogle Scholar
• SteinerJFProchazkaAVThe assessment of refill compliance using pharmacy records: methods, validity, and applicationsJ Clin Epidemiol19975011051169048695
   PubMed Web of Science ®Google Scholar
• NeumannPJCohenJTWeinsteinMCUpdating cost-effectiveness – the curious resilience of the $50,000-per-QALY thresholdN Engl J Med2014371979679725162885
   PubMed Web of Science ®Google Scholar
• BraithwaiteRSMeltzerDOKingJTJrLeslieDRobertsMSWhat does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?Med Care200846434935618362813
   PubMed Web of Science ®Google Scholar
• WuEQBirnbaumHGMarevaMNCost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic painJ Pain20067639940716750796
   PubMed Web of Science ®Google Scholar
• BeardSMMcCrinkLLeTKGarcia-CebrianAMonzBMalikRACost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UKCurr Med Res Opin200824238539918157921
   PubMed Web of Science ®Google Scholar
• O’ConnorABNoyesKHollowayRGA cost-utility comparison of four first-line medications in painful diabetic neuropathyPharmacoeconomics200826121045106419014205
   PubMed Web of Science ®Google Scholar
• BellowsBKDahalAJiaoTBiskupiakJA cost-utility analysis of pregabalin versus duloxetine for the treatment of painful diabetic neuropathyJ Pain Palliat Care Pharmacother201226215316422509775
   PubMedGoogle Scholar
• CarlosFRamírez-GámezJDueñasHGalindo-SuárezRMRamosEEconomic evaluation of duloxetine as a first-line treatment for painful diabetic peripheral neuropathy in MexicoJ Med Econ201215223324422082033
   PubMedGoogle Scholar
• DworkinRHBackonjaMRowbothamMCAdvances in neuropathic pain: diagnosis, mechanisms, and treatment recommendationsArch Neurol200360111524153414623723
   PubMed Web of Science ®Google Scholar
• TanTBarryPRekenSBakerMGuideline Development GroupPharmacological management of neuropathic pain in non-specialist settings: summary of NICE guidanceBMJ2010340c107920335333
   PubMedGoogle Scholar
• SchumockGTWaltonSMParkHYFactors that influence prescribing decisionsAnn Pharmacother200438455756214966259
   PubMed Web of Science ®Google Scholar